Newsfeeds - Spark Newswire

5 minute read

Sutro Biopharma Reports Interim Data From Dose-Expansion Cohort Of STRO-002 Phase 1 Study For Patients With Advanced Ovarian Cancer: ‘33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients’

Today, 2:01 AM

- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. - Dose response was observed, with a 47% ORR in 17 patients who started at

STRO

2 minute read

The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week

By Shanthi Rexaline

Today, 2:01 AM

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year.

AVTX

2 minute read

Earnings

Sutro Biopharma Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 2:01 AM

Benzinga Pro data, Sutro Biopharma (NASDAQ:STRO) reported Q3 sales of $8.52 million. Earnings fell to a loss of $34.67 million, resulting in a 253.64% decrease from last quarter.

STRO

1 minute read

Merck, Sutro Biopharma Extends Cytokine Derivative Research Program

By Vandana Singh

Today, 2:01 AM

Merck & Co Inc (NYSE:MRK) has extended the research term by two years for the first cytokine derivative program under a…

MRK

1 minute read

News

Sutro Biopharma Announces Extension Of Cytokine Derivative Research Program Under Collaboration With Merck

By Benzinga Newsdesk

Today, 2:01 AM

Sutro Biopharma, Inc. (NASDAQ:STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer

MRK

2 minute read

Earnings

Sutro Biopharma Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 2:01 AM

According to Benzinga Pro data, during Q2, Sutro Biopharma (NASDAQ:STRO) posted sales of $28.05 million. Earnings were up 48.42%, but Sutro Biopharma still reported an overall loss of $9.80 million.

STRO

1 minute read

Sutro Biopharma’s Ovarian Cancer Candidate Fast Tracked In US

By Vandana Singh

Today, 2:01 AM

The FDA has granted Fast Track designation to Sutro Biopharma Inc’s (NASDAQ:STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant epithelial ovarian,…

STRO

6 minute read

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

By Shanthi Rexaline

Today, 2:01 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)

ABBV

1 minute read

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation For Patients With Advanced Ovarian Cancer

By Bill Haddad

Today, 2:01 AM

STRO

1 minute read

Sutro Biopharma Q2 EPS $(0.13) Up From $(0.60) YoY, Sales $28.05M Up From $9.47M YoY

By Luke J Jacobi

Today, 2:01 AM

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.13) per share. This is a 78.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported $28.05 million in

STRO